Arimidex 1mg/tab 50 Tabletten by Para Pharma

Usage

1. Establish your baseline — obtain serum LH, FSH, total testosterone, and oestradiol via immunoassay before the first dose so you have a documented starting point for measuring recovery progress.
2. Begin at 1 mg daily once circulating androgen levels have declined to a level where aromatase substrate is still falling but oestradiol has not yet risen sharply — typically 10–14 days after the last long-ester injection or immediately after an oral-only cycle clears.
3. At the midpoint of your planned protocol length, repeat the oestradiol panel: if oestradiol is within the target range (roughly 20–30 pg/mL by sensitive assay), reduce to the 0.5 mg maintenance dose; if still elevated, continue at 1 mg.
4. Continue the maintenance phase until LH and FSH are measurably trending toward reference range on consecutive monthly panels — for longer or heavier cycles this may mean sustaining anastrozole for ten to fourteen weeks total.
5. Taper the dose in the final one to two weeks of the protocol: 0.5 mg every other day before stopping, to prevent an abrupt rebound in oestradiol as CYP19A1 inhibition is withdrawn.
6. Obtain a final post-PCT lab panel — total testosterone, LH, FSH, and oestradiol — at least two weeks after the last tablet to confirm autonomous HPG axis function has been restored before concluding the PCT course.

Warnings

Frequently asked questions

How many weeks does a complete anastrozole PCT typically run from start to finish?

Complete PCT duration ranges from approximately three to fourteen weeks depending on suppression depth. Shorter, less suppressive cycles usually require three to five weeks of anastrozole use. Moderate cycles commonly demand seven to ten weeks. Heavily suppressive stacks may extend the aromatase-inhibition phase to twelve weeks or beyond, guided by mid-protocol LH, FSH, and total testosterone results via standard immunoassay.

Can running anastrozole for too long during PCT actually cause problems?

Yes. Extending anastrozole beyond the point where oestradiol has naturally normalised risks driving oestradiol below the physiological range. Suppressed oestradiol in men is associated with reduced libido, joint discomfort, and impaired bone turnover. Mid-cycle oestradiol monitoring — ideally by sensitive mass spectrometry assay — allows the practitioner to identify when CYP19A1 inhibition should be tapered or discontinued.

Under what circumstances can PCT with anastrozole be legitimately shortened?

PCT can be shortened when mid-protocol bloodwork confirms that LH, FSH, and total testosterone have returned to within-reference values ahead of the projected timeline. This scenario is more common after lighter exposures or in individuals with faster intrinsic HPG axis resilience. Documented lab confirmation — not subjective symptom resolution — is the appropriate criterion for early discontinuation.

Can Para Pharma Anastrozole 1mg tablets be split to adjust the dose during a longer PCT?

Yes. The 1 mg tablet format allows splitting to reach a 0.5 mg dose for the maintenance phase of a longer protocol. Once the induction phase has reduced oestradiol toward the target range — confirmed by sensitive immunoassay — a halved tablet every day or every other day provides continued CYP19A1 inhibition at a level appropriate for a stabilising hormonal environment.

Why does a 50-tablet pack make practical sense for managing PCT duration?

A 50-tablet count covers every clinically relevant PCT duration without requiring a mid-protocol reorder. At 1 mg daily for five weeks, the pack is fully consumed; at a split 0.5 mg daily dose across a fourteen-week protocol, the same pack provides exactly the right supply. This flexibility makes the Para Pharma 50-tab format suitable for both shorter recovery windows and extended post-cycle programmes. (2) angle_used

Manufacturer

Para Pharma's quality assurance approach for its oral tablet programme at the 1 mg API level addresses a specific technical concern that distinguishes low-dose solid-dose forms from higher-strength counterparts: that a 1 mg declared value per tablet requires the validated compression process to distribute the active ingredient without any inter-unit variance that would be masked by batch-average testing alone. For this Anastrozole product, the resolution is discrete-tablet HPLC sampling — individual units drawn from multiple compression-run positions are each extracted and assayed independently, producing unit-specific content data rather than a pooled result. Sterility and aseptic conditions govern the entire manufacturing environment; LAL (Limulus Amebocyte Lysate) endotoxin testing is completed before any batch proceeds to final packaging, and GMP documentation tracks the product from API release through finished blister sealing under controlled environmental conditions.